昭衍新藥(603127.SH)擬參與競拍上海斯萊克實驗動物有限責任公司80%股權
格隆匯1月21日丨昭衍新藥(603127.SH)公佈,根據上海聯合產權交易所披露的關於上海斯萊克實驗動物有限責任公司(下稱“標的公司”)80%股權的轉讓信息,中國科學院上海生命科學研究院擬公開掛牌轉讓所持標的公司80%股權,掛牌底價為人民幣1.32億元。基於未來業務拓展需要和長期戰略考量,公司擬參與競拍上海斯萊克實驗動物有限責任公司80%股權。
標的公司在國內實驗動物領域佔有重要地位,是國內自主研發生產實驗動物行業實力較強、體量較大的企業,其所供應的動物質量和數量均位居全國領先地位,擁有許多特有的實驗動物品系,與全國幾百家客户有業務合作,包括科研院所、高等院校、醫院、製藥企業、生物醫藥研發機構、CRO公司等。公司從事的是臨牀前研究服務業務,每年需要採購大量的實驗動物用於臨牀前實驗,公司通過收購標的公司的80%股權,一方面可以延長業務鏈條,保障公司日常實驗所需要的實驗動物供給,降低實驗動物價格上升對公司的不利影響;另一方面可以將標的公司納入合併報表,豐厚公司的經營業績,進一步提高公司的競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.